Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director
Leiden, the Netherlands, April 30, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that the Company’s 2025 Annual General Meeting of Shareholders (the “AGM”) will be held on Wednesday June 11, 2025, at 14:00 CEST. The Notice to Convene, Explanatory Notes, Proxy and other meeting documents for the AGM can be found on the Company’s website under Investors/Shareholder Meetings.
The Board of Directors has decided to nominate Dr. Elaine Sullivan at the AGM for the appointment as a new Non-Executive Director for a term of four years. The terms of Mrs. Deborah Jorn and Mr. Steven Baert are scheduled to expire at the AGM and they are not available for reappointment.
The agenda of the AGM also includes the reappointments of Mrs. Jabine van der Meijs and Mr. Leonard Kruimer as Non-Executive Directors, the proposal to reappoint Deloitte Accountants B.V. as the external auditor of the Company for the financial year 2025, and the renewal of the authorizations for the Board of Directors to issue shares (including rights to acquire shares), and to repurchase shares.
The AGM will be held at the Corpus Congress Centre, Willem Einthovenstraat 1, 2342 BH in Oegstgeest, the Netherlands, and will be webcast live.
Profile
Dr. Elaine Sullivan (date of birth: February 6, 1961, British and Irish citizen) is a senior executive, with a successful track record in developing novel medicines, business development, fund investments and start-ups. Dr. Sullivan has international experience in the pharmaceutical and biotech industry, having lived and worked in Ireland, UK, Switzerland, and the US, delivering novel drug projects, commercial partnerships and implementing breakthrough technologies.
Dr. Sullivan has served as Non-Executive Director at Zealand Pharma A/S (listed on NASDAQ Copenhagen, “ZEAL”), a biotechnology company focused on the discovery and development of peptide-based medicines, since 2024. She has also served as Senior Non-Executive Director at hVIVO, previously known as Open Orphan plc, listed on the London Stock Exchange AIM market (“HVO”) since 2020. hVIVO is a contract research organization which is a world leader in human challenge clinical trials.
Prior thereto, Dr. Sullivan gained global leadership experience, including membership of the senior global R&D management teams at Eli Lilly and Company (US) and AstraZeneca (UK), and also served as Non-Executive Director at various public companies, including IP Group plc, Evotec AG, Active Biotech AB and Nykode Therapeutics ASA, including membership in audit, remuneration, ESG and nomination committees.
Dr. Sullivan holds a PhD in Molecular Virology (University of Edinburgh) and a BSc (Hons) in Molecular Biology (University of Glasgow, UK).
The resume of Dr. Sullivan has been uploaded as part of the meeting documents for the AGM. Dr. Sullivan will introduce herself to our shareholders during the AGM.
About Pharming Group N.V.
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are commercializing and developing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.
For more information, visit and find us on .
Inside Information
This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
For further public information, contact:
Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E:
FTI Consulting, London, UK
Simon Conway/Alex Shaw/Amy Byrne
T: 0
LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: 27
E:
Attachment
